Press Releases

Press Releases

Summary Toggle PDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 Million

INCLINE VILLAGE, Nev. , Dec. 16, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced today that its Board of Directors has authorized a $75 million increase to the $200 million common stock and convertible notes repurchase authorization that was previously

Dec 16, 2019
Summary Toggle PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024

INCLINE VILLAGE, Nev. , Dec. 13, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of its

Dec 13, 2019
Summary Toggle PDL BioPharma Announces Completion of Strategic Review Process

Will Pursue Monetization of its Assets and Optimal Means of Returning Proceeds to Shareholders; Will Cease Making Additional Strategic Acquisitions and Investments Board Authorizes Repurchase Program to Acquire up to $200 Million of Outstanding PDL Stock and Convertible Notes Conference Call at

Dec 9, 2019
Summary Toggle PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®

INCLINE VILLAGE, Nev. , Dec. 3, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ: EVFM) on its recent achievement of two major regulatory and clinical milestones with its lead product candidate Amphora ®

Dec 3, 2019
Summary Toggle PDL BioPharma Reaffirms Commitment To Shareholder Value Creation

Responds to Escalation of Engine Capital's Public Campaign INCLINE VILLAGE, Nev. , Nov. 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today issued the following statement in response to Engine Capital LP's ("Engine") escalation of its public campaign

Nov 14, 2019
Summary Toggle PDL BioPharma Reports 2019 Third Quarter Financial Results

Revenues of $44.2 million includes continued growth from LENSAR and strong contribution from royalty assets Conference call at 4:30 p.m. Eastern time today INCLINE VILLAGE, Nev. , Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for

Nov 6, 2019
Summary Toggle PDL BioPharma to Announce Third Quarter 2019 Financial Results on November 6, 2019

INCLINE VILLAGE, Nev. , Oct. 30, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter 2019 financial results for the period ended September 30, 2019 , on Wednesday, November 6, 2019 , after market close.

Oct 30, 2019
Summary Toggle PDL BioPharma Responds to Letter from Engine Capital

INCLINE VILLAGE, Nev. , Oct. 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that Harold E. Selick , Ph.D., Chairman of the Board of Directors of PDL BioPharma , has sent the following letter to Engine Capital, LP .

Oct 24, 2019
Summary Toggle PDL BioPharma to Participate in the 2019 Cantor Fitzgerald Global Healthcare Conference

INCLINE VILLAGE, Nev. , Sept. 26, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019 ,

Sep 26, 2019
Summary Toggle PDL BioPharma Announces Private Exchange of Approximately $86.1 Million of Convertible Notes Due 2024

INCLINE VILLAGE, Nev. , Sept. 12, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate privately negotiated transactions to exchange approximately $86.1 million in aggregate principal amount of its 2.75% Convertible

Sep 12, 2019
Summary Toggle PDL BioPharma Announces Favorable Decision in Wellstat Diagnostics Litigation

INCLINE VILLAGE, Nev. , Sept. 11, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that the Supreme Court of New York , County of New York , Commercial Division, issued its decision today in PDL's previously disclosed litigation related to defaults by

Sep 11, 2019
Summary Toggle PDL BioPharma Reports 2019 Second Quarter Financial Results

INCLINE VILLAGE, Nev. , Aug. 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2019 : Second Quarter and Recent Financial Highlights Generally Accepted Accounting Principles ("GAAP") net loss

Aug 7, 2019
Summary Toggle PDL BioPharma to Announce Second Quarter 2019 Financial Results on August 7, 2019

INCLINE VILLAGE, Nev. , July 31, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its second quarter 2019 financial results for the period ended June 30, 2019 , on Wednesday, August 7, 2019 , after market close.

Jul 31, 2019
Summary Toggle PDL BioPharma Announces Departure of CFO

INCLINE VILLAGE, Nev. , June 25, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the resignation of Chief Financial Officer, Peter Garcia , who will be leaving the Company effective August 15, 2019 . He will continue in his role through the filing

Jun 25, 2019
Summary Toggle Natasha A. Hernday Elected to PDL BioPharma's Board of Directors

INCLINE VILLAGE, Nev. , June 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that at its 2019 annual meeting of stockholders held June 20, 2019 , the Company's stockholders elected Natasha A. Hernday to the Company's Board of Directors.

Jun 24, 2019